Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.

DMX died at age 501. Here's everything to know about his cause of death and a look at the impact the hip-hop star left on ...

Explore DMX's net worth journey, career success, legal issues, and legacy. Discover how the rap icon went from global fame to ...

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

DMX's former wife, Tashera Simmons, hopes to help heal others by telling her story, one painful chapter at a time, in new ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

DMX’s estate wins an IP fight with his ex-wife, Nelly’s ex-bandmate drops his case, Soulja Boy faces a $4 million verdict and more music law news.

The US Food and Drug Administration (FDA) has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ...

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and ...